Clinical Trial

First Time in Human Study of Long Acting VH4524184 Formulations

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.
Protocol Amendment History 1 change
notable Enrollment increased: 268 -> 372 participants 2026-07-01
Trial Details
NCT Number NCT06310551
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 372 participants
Start Date 2024-03-21
Primary Completion 2028-01-21 (estimated)
Study Completion 2028-01-21 (estimated)
Updated on ClinicalTrials.gov 2026-08-10